MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 25, 2006; DOI: 10.1124/mol.106.025478


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.025478v1
70/4/1246    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daulhac, L.
Right arrow Articles by Fialip, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daulhac, L.
Right arrow Articles by Fialip, J.


Received for publication April 14, 2006.
Revised July 17, 2006.
Accepted for publication July 20, 2006.

Diabetes-induced mechanical hyperalgesia involves spinal MAPKs activation in neurons and microglia via NMDA-dependent mechanisms

Laurence Daulhac 1*, Christophe Mallet 2, Christine Courteix 1, Monique Etienne 2, Eliane Duroux 1, Anne-Marie Privat 1, Alain Eschalier 3, Joseph Fialip 1

1 INSERM U766, Faculte de Pharmacie, Laboratoire de Pharmacologie 2 INSERM U766, Faculte de Medecine, Laboratoire de Pharmacologie Medicale 3 IINSERM U766, Faculte de Medecine, Laboratoire de Pharmacologie Medicale

* Address correspondence to: E-mail: laurence.daulhac{at}u-clermont1.fr

Abstract

Molecular mechanisms underlying diabetes-induced painful neuropathy are poorly understood. In the streptozotocin-induced diabetic rats, we have demonstrated that mechanical hyperalgesia, a common symptom of diabetic neuropathy, was correlated with an early increase of ERK, p38 and JNK phosphorylation in the spinal cord and dorsal root ganglion at three weeks of the diabetes. This change was specific of hyperalgesia because non hyperalgesic rats failed to have such an increase. Immunoblots analysis showed no variation of protein levels, suggesting a post-translational regulation of the corresponding kinases. In diabetic hyperalgesic rats, immunocytochemistry revealed that all phosphorylated MAPKs colocalized both with the neuronal (NeuN) and microglial (OX42) cell-specific markers but not with the astrocyte marker (GFAP) in the superficial dorsal horn-laminae of the spinal cord. In these same rats, a seven-day administration (5 µg/rat/day, i.t.) of U0126, SB203580 and SP600125, which inhibit MEK, p38 and JNK respectively, suppressed mechanical hyperalgesia and decreased phosphorylation of the kinases. To characterize the cellular events upstream of MAPKs, we have examined the role of the NMDA receptor known to be implicated in pain hypersensitivity. The prolonged blockade of this receptor during seven days by MK801 (5 µg/rat/day, i.t.), a non-competitive NMDA receptor antagonist, reversed hyperalgesia developed by diabetic rats and blocked phosphorylation of all MAPKs. These results demonstrate for the first time that NMDA receptor-dependent phosphorylation of MAPKs in spinal cord neurons and microglia contribute to the establishment and chronic maintenance of painful diabetic hyperalgesia and that these kinases represent potential targets for pain therapy.


Key words: Glutamate, MAP Kinase, Jun Kinase, P38 MAP Kinase, Synaptic plasticity


This article has been cited by other articles:


Home page
J. Physiol.Home page
X.-L. Wang, H.-M. Zhang, S.-R. Chen, and H.-L. Pan
Altered synaptic input and GABAB receptor function in spinal superficial dorsal horn neurons in rats with diabetic neuropathy
J. Physiol., March 15, 2007; 579(3): 849 - 861.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics